been shown that substituted quinolines stimulate gap junction activity, decrease alpha survivin expression, and subsequently inhibit cancer cell growth. Our findings demonstrate that PQ15 has a promising role in exerting anti-cancer activity in human breast cancer cells.
Introduction
The influence of hormones on the development and differentiation of the mammary gland has been described in numerous publications in regard to the role of estrogen in ductal growth, progesterone in lobulo-alveolar development, and prolactin in milk secretion [1] . However, the mechanism by which this local control of growth and differentiation of the constituent epithelial cell types occur is unclear. Some candidates are locally-acting growth factors, epithelial-stromal interactions, and direct cell-cell communication [2] . Direct cell-cell communication such as gap junctions may be modulators underlying cellular differentiation and also co-ordinates of cellular function in the mammary gland.
Numerous reports have been confirmed that gap junctions are frequently decreased or absent in cancer cells [3] . For instance, co-culture of tumor cells with normal cells, or with connexin-overexpressing cells, results in growth retardation of neoplastic component by the establishment of functional communication as observed with dye transfer [4] . This retardation of tumor growth could be prevented by co-culturing transformed cells with junctional competent normal cells transfected with a connexin-specific antisense reagent [5] . Thus, these results indicate that signals from adjacent normal cells can reverse a malignant phenotype and that their failure to accomplish this is due to a lack of GJIC.
The loss of GJIC during carcinogenesis may not result from a direct disruption of a specific connexin gene or mRNA levels. The cellular oncogenes downregulate GJIC by phosphorylating gap junction proteins, connexin 32 (Cx32) and connexin 43 (Cx43). In the case of Cx43, the phosphorylation of C-terminal serine residues results directly from protein kinase C (PKC) [6] .
Furthermore, evidence demonstrated that PKCs inhibit gap junction channels by inhibiting gap junction assembly and channel gating [7] . PKC α overexpression has been shown to cause tumor growth, and tumor resistance to cytotoxic chemotherapy. We have shown that PKC  is highly expressed in MCF-7 breast cancer cells and stimulation of PKC  in these cells caused a further inhibition of gap junction activity [8] .
Several studies involving breast cancer patient tissue samples show a loss of overall connexin protein expression or a relocalization of the connexin to intracellular compartments [9] [10] [11] . Multiple in vitro studies confirm the loss of connexin and/or GJIC in breast cancer cells.
Early studies showed that connexin 26 (Cx26) and Cx43 were downregulated at the mRNA level in primary cells derived from human breast tumors [11] as well as in breast cancer cell lines [10] . Furthermore, extensive studies involving the reconstitution of connexin expression in GJIC-deficient breast cancer cell lines have shed some light on their role in cell growth control and differentiation. Re-expression of Cx43 in MDA-MB-435 breast cancer cells resulted in growth suppression, a regained ability to differentiate into three-dimensional (3D) structures in the presence of a basement membrane and, importantly, reduction of tumor growth in mice [12] .
Interestingly, increasing cell-cell communication in Cx43 overexpressing tumor cells enhances drug sensitivity [13] . Cancer cells are characterized by the lack of growth control, by the inability to terminally differentiate and by resistance to apoptosis. Additionally, connexins have shown to have a GJIC-independent role in the regulation of apoptosis, as suggested from the correlation of intracellular Cx26 and Cx43 expression with the presence of the proapoptotic factor Bak [9] . Previous work demonstrated that first and second generations of substituted quinolines can activate apoptotic protein, caspase 3, in addition to upregulation gap junction activity in breast cancer cells [14] . This supports the idea that reversed process such as increase or gain of GJIC in cancer cells can drive toward apoptosis of breast cancer cells.
Furthermore, transfection of gap junction genes, connexins, into GJIC-deficient tumor cells can restore GJIC, growth control and reduce tumorigenicity [15] . The modulation can either downregulate GJIC and lead to tumor promotion or it can upregulate GJIC and lead to suppression of the initiated cells [16] . Hence, increasing gap junction activity or enhancing GJIC in tumor cells provides the means to enhance antineoplastic therapies.
Based on previous synthesis, we designed and synthesized structurally similar analogs with enhanced bioactivity and improved drug characteristics, affording lead compounds suitable for preclinical development. Structure-activity relationship (SAR) studies allowed us to optimize the potency of these compounds through iterative medicinal/combinatorial chemistry, molecular modeling and in vitro testing. Therefore, this report demonstrates that the third generation of subsitituted quinoline, PQ15 (Figure 1 ), can increase gap junction activity in T47D breast cancer cells and significantly cause a decrease in the expression of α-survivin.
Materials and Methods

Synthesis of PQs:
A small library of PQ1 -PQ5 was first synthesized and PQ1, containing an aminopropyl side chain at N1', was found to be the most active compound in both GJIC enhancement and anticancer activities among PQ1 -PQ5 (PQ2 -PQ5 are inactive and the data were not shown). Hence, analogs of PQ1, PQ6 -PQ11, were synthesized by varying the N1' substituent and studied their anticancer activities. Fortuitously, PQ11 containing a furanylmethyl moiety (maintains a similar distance as that of the aminopropyl moiety of PQ1) at N1' side chain shows potent anticancer activity with an IC 50 value of 15.6 nM.
The syntheses of PQ1 and PQ11 have been reported by us [17] and the synthesis of Western blots were detected by enhanced chemiluminescence detection reagents (Pierce, Rockford, Illinois, USA).
Trypan Blue Excision. Cell viability was measured using the trypan blue excision method. 1 x cell suspension was mixed with trypan blue dye and then visually examined for viable cells by the Cellometer Auto T4 (Nexcelom). The graphical presentation includes at least three independent samples.
Statistical analysis:
The level of significance (see * in figure legends) was considered at p < 0.05 using Student's t test analysis. All data are presented as mean ± S.D. of at least three independent experiments from different batches of cultures.
Results and Discussion
Approximately one in eight women is affected by breast cancer, which is the leading cause of death in females between the ages of 40 and 50 years in the Western world [18] . Antibreast cancer agents include tamoxifen (Nolvadex R ; partial antiestrogens), fulvestrant (Faslodex R ; pure antiestrogens), and Lapatinib (Tykerb A third generation of substituted quinolines was designed and their enhancement of GJs activities and killing of human breast cancer cells was demonstrated. PQ15 was tested on the effect of GJIC activity in T47D breast cancer cells (Figure 2A-H) . The results demonstrated that 100 nM of PQ15 showed a significant increase in gap junction activity compared to controls, without PQ15 treatment, using scrape load/dye transfer assay ( Figure 2D ). However, 1000 nM PQ15 did not significantly increase the gap junction activity ( Figure 2F ). This may due to the cytotoxic effect at a higher concentration. Furthermore, the increase of gap junction activity by 100 and 200 nM PQ15 can be inhibited by 12-O-tetradecanoylphorbol-13-acetate (TPA) ( Figure   2G -H). Previously, TPA has been shown to activate protein kinase C (PKC) and subsequently phosphorylate Cx43 on serine 262 and serine 268 [19] . less potent its precursors [14, 20] . This indicates that the structure of highly quinolines in PQ15
is affecting the function of GJIC enhancement in T47D cells.
The effect of PQ15-upregulated gap junction activity in T47D cell proliferation was examined. T47D cells were treated with 0, 10, 100, 200 and 1000 nM PQ15 for 48 hours. A graphical presentation of three experiment results is presented in Figure 3 . The results show that 10 nM PQ15 is not sufficient to affect cell proliferation; however, 100, 200 and 1000 nM PQ15 cause a significant decrease of 18%, 30%, and 32%, respectively, in cell proliferation compared to control or DMSO. This suggests that 200 nM PQ15 can cause an increase in gap junction activity and subsequently can decrease cell proliferation of T47D cells. Furthermore, cell viability of T47D cells was also performed (Figure 4) . A 100 nM or 200 nM PQ15 for 48 hours reduces 16% of T47D cell viability and 1000 nM PQ15 has a greater effect with 36% decrease in cell viability compared to control or DMSO. This supports the previous observation where 1000 nM PQ15 has less gap junction activity than 100-200 nM PQ15. The loss of cellcell interaction is due to cytotoxic effect of PQ15 at 1000 nM.
Furthermore, whole cell extract of PQ15 treatment was analyzed for the changes in gap junctional proteins, connexins. Cells were treated with 10, 100, and 1000 nM PQ15 for 24
hours. Western blot analysis was performed against Cx43 ( Figure 5A ). The results show that PQ15 has no effect on the total Cx43 expression; however, PQ15 causes a decrease in the phosphorylation of Cx43. This suggests that the increase of gap junction activity by PQ15 is due to the inhibition of phosphorylation of Cx43. The result also confirms that PQ15 and TPA mediate gap junction activity through the phosphorylation of Cx43.
Alpha-survivin expression is upregulated in human cancers and associated with resistance to chemotherapy, suggesting that α-survivin prolongs the survival of cancer cells.
The next step was to determine whether PQ15 affects the survival pathway of T47D cells. Cells were treated with 0, 10, 100, and 1000 nM PQ15 for 24 hours ( Figure 5B ). The results show that 100-1000 nM PQ15 can cause a significant decrease of α-survivin expression compared to control or DMSO. This supports that PQ15 inhibits the expression of α-survivin, preventing cell survival, and subsequently decreases the cell viability of T47D cells.
In conclusion, the anti-cancer activity of PQ15 in T47D cells is less potent as that of PQ1
and PQ11. The results imply that replacement of the furan moiety of the appendage at C8-amine decreases potency. However, it is important to find that an addition of a quinoline nucleus to the aminoquinoline PQ does not impede the anticancer activity. From an immunoprecipitation assay, it was found that PQ disrupts the interaction of Cx43 and Nedd4, an 
